Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-11-11 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi + Imjudo approved in US for lung cancer
Regulatory Filings Classification · 1% confidence The document begins with 'National Storage Mechanism' and prominently features an 'RNS Number' (0665G) and the date '11 November 2022'. The content is a press release announcing the US FDA approval of AstraZeneca's drugs (Imfinzi and Imjudo) for metastatic NSCLC, based on Phase III trial results. This format—a brief announcement of a significant corporate event or regulatory update, distributed via the RNS system (which is explicitly mentioned as the provider)—is characteristic of a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dedicated earnings release (ER), the most appropriate classification is the general regulatory filing category, RNS.
2022-11-11 English
YTD AND Q3 2022 RESULTS
Foreign Filer Report
2022-11-10 English
YTD and Q3 2022 Results
Earnings Release Classification · 1% confidence The document text explicitly states 'YTD and Q3 2022 results', provides detailed financial tables comparing YTD 2022 vs YTD 2021 and Q3 2022 vs Q3 2021, discusses revenue, EPS, gross margin, and updates FY 2022 guidance. This content structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it contains comprehensive financial performance details, key milestones, and guidance updates, it is more comprehensive than a typical 'Earnings Release' (ER) which usually contains only highlights. However, the document is dated November 10, 2022, and discusses Q3 2022 results. A comprehensive report covering a period shorter than a year is classified as an Interim/Quarterly Report (IR). The document also mentions a conference call for 'today, 10 November 2022', suggesting this is the primary release document detailing the results, not just an announcement of the report (RPA). Therefore, IR is the most appropriate classification. Q3 2022
2022-11-10 English
Earnings Release 2022
Earnings Release Classification · 1% confidence The document explicitly presents 'YTD and Q3 2022 results' with detailed tables summarizing Revenue, EPS, financial performance commentary, key milestones, and updated guidance for the full year 2022. The structure, content (financial metrics, commentary from the CEO, and forward-looking guidance), and the mention of specific quarterly results (Q3 2022) strongly indicate this is a periodic financial results announcement, not a comprehensive annual report (10-K) or a brief announcement of a report (RPA). Since it contains the initial announcement of periodical financial results (Q3 2022), the most appropriate classification is Earnings Release (ER). It is too detailed for just an RPA, and it is not the full annual report (10-K). Q3 2022
2022-11-10 English
FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA
Foreign Filer Report
2022-11-09 English
FDA Advisory Committee recommends PT027 in asthma
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the date format typical of regulatory news service announcements. The content details a positive recommendation from the FDA advisory committee (PADAC) regarding a drug (PT027) and includes extensive clinical trial data (MANDALA, DENALI). This type of announcement, which disseminates material, time-sensitive, non-periodic corporate information via a regulatory news service, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR), a management discussion (MDA), or a formal earnings release (ER). Since it is a general regulatory announcement disseminated through RNS, RNS is the most appropriate code.
2022-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.